ZG-001(Hunan Warrant Pharmaceutical)

To study the tolerance and pharmacokinetics of a single oral administration of different doses of ZG-001 capsules in healthy subjects, to study the tolerance and pharmacokinetics of multiple oral administration of different doses of ZG-001 capsules in healthy subjects, and to study the effect of diet on the pharmacokinetics of oral ZG-001 capsules in healthy subjects, so as to provide a basis for later clinical trials.

Primary Objectives: To quantitatively analyze the total radioactivity in excrement (urine and feces) of healthy male participants after oral administration of [14C] ZG-001 capsules, obtain data on radioactivity recovery in the human body, and determine the main excretion pathway; to determine the radiometabolite profiles in plasma, urine, and feces of healthy male participants after oral administration of [14C] ZG-001 capsules and identify the main metabolites, providing data on the main metabolic pathways of ZG-001 in the human body and determining the main biotransformation pathways; to investigate the pharmacokinetic characteristics of total radioactivity of [14C] ZG-001 in whole blood and plasma of healthy male participants, and to investigate the distribution of total radioactivity in whole blood and plasma. Secondary Objectives: To quantitatively analyze the concentrations of parent ZG-001 and its metabolite ZG-001-M3 in plasma, obtain the pharmacokinetic parameters of the corresponding analytes in plasma; to observe the safety of participants after a single oral dose of [14C] ZG-001 capsules.